13 January 2026 : Clinical Research
Comparative Outcomes of Tricuspid-Dedicated Versus Non-Dedicated Devices in Transcatheter Tricuspid Edge-to-Edge Repair
Adam Rdzanek
ABCDEF 1, Adam Piasecki ABCDEF 1, Mariusz Tomaniak ADE 1*, Ewa Pędzich ADE 1, Ewa Ostrowska BE 1, Paweł Pawłowicz BE 1, Agnieszka Kapłon-Cieślicka BE 1, Piotr Scisło ABE 1
DOI: 10.12659/MSM.950175
Med Sci Monit 2026; 32:e950175
Table 1 Baseline characteristics of the study population.
| Parameter | OverallN=44 | Non-dedicated (MitraClip) N=22 | Dedicated (TriClip or PASCAL) N=22 | P value |
|---|---|---|---|---|
| Age, years | 74.7 (7.5) | 73.4 (8.8) | 76.0 (5.9) | 0.26 |
| Women | 26 (59.1%) | 10 (45.5%) | 16 (72.7%) | 0.12 |
| Atrial fibrillation | 42 (95.5%) | 20 (90.0%) | 22 (100%) | 0.49 |
| Atrial fibrillation (permanent) | 32 (72.7%) | 16 (72.7%) | 16 (72.7%) | 0.99 |
| CAD | 23 (52.3%) | 11 (50.0%) | 12 (54.5%) | 0.76 |
| PAD | 3 (6.8%) | 2 (9.1%) | 1 (4.5%) | 0.99 |
| Hypertension | 35 (79.5%) | 16 (72.7%) | 19 (86.4%) | 0.46 |
| Diabetes | 11 (25.0%) | 6 (27.3%) | 5 (22.7%) | 0.73 |
| Diabetes, insulin | 1 (2.3%) | 1 (4.5%) | 0 (0.0%) | 0.31 |
| CKD | 36 (81.8%) | 18 (81.8%) | 18 (81.8%) | 0.99 |
| COPD/asthma | 10 (22.7%) | 4 (18.2%) | 6 (27.3%) | 0.47 |
| Connective tissue disease | 4 (9.1%) | 3 (13.6%) | 1 (4.5%) | 0.99 |
| MI | 14 (31.8%) | 6 (27.3%) | 8 (36.4%) | 0.52 |
| Stroke/TIA | 5 (11.4%) | 1 (4.5%) | 4 (18.2%) | 0.15 |
| PCI | 12 (27.3%) | 7 (31.8%) | 5 (22.7%) | 0.50 |
| CABG | 5 (11.4%) | 3 (13.6%) | 2 (9.1%) | 0.99 |
| AVR | 3 (6.8%) | 1 (4.5%) | 2 (9.1%) | 0.55 |
| Ablation | 9 (20.5%) | 2 (9.1%) | 7 (31.8%) | 0.13 |
| Cardiac implantable device | 23 (52.3%) | 14 (63.6%) | 9 (40.9%) | 0.13 |
| Hemoglobin | 12.3 (1.9) | 11.9 (2.1) | 12.1 (1.7) | 0.95 |
| Platelet count | 179.0 (67.0) | 169.6 (74.0) | 189.6 (67.5) | 0.07 |
| C-reactive protein | 2.2 (4.9) | 2.6 (7.2) | 2.2 (4.3) | 0.52 |
| Urea | 56.7 (25.4) | 39.0 (34.0) | 64.6 (26.7) | 0.18 |
| Creatinine | 1.4 (0.5) | 1.4 (0.7) | 1.5 (0.3) | 0.88 |
| eGFR | 47.3 (22.7) | 52.8 (26.9) | 34.0 (19.0) | 0.85 |
| AST | 31.0 (10.0) | 31.8 (5.1) | 31.0 (10.0) | 0.29 |
| ALT | 23.0 (10.0) | 23.2 (6.5) | 23.0 (8.0) | 0.74 |
| Bilirubin | 0.71 (0.46) | 1.0 (0.4) | 0.8 (0.7) | |
| INR | 1.27 (0.48) | 1.4 (0.3) | 1.2 (2.0) | 0.81 |
| NT-proBNP | 2168 (1679) | 2651 (1774) | 1786 (854) | |
| Na | 139.7 (3.9) | 140.0 (2.6) | 138.6 (3.7) | 0.84 |
| Furosemide | 25 (56.8%) | 12 (54.5%) | 13 (59.1%) | 0.90 |
| Daily dosage | 145.2 (98.7) | 140.0 (97.7) | 150.8 (103.5) | 0.39 |
| Torsemide | 31 (70.5%) | 13 (59.1%) | 18 (81.8%) | 0.15 |
| Daily dosage | 20.0 (15.0) | 20.0 (18.0) | 17.5 (15.0) | 0.80 |
| Hydrochlorothiazide | 6 (13.6%) | 3 (13.6%) | 3 (13.6%) | 0.99 |
| Daily dosage | 25.0 (6.0) | 25.0 (0.0) | 25.0 (0.0) | 0.70 |
| Indapamide | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| Daily dosage | – | – | – | |
| Spironolactone | 7 (15.9%) | 4 (18.2%) | 3 (13.6%) | 0.70 |
| Daily dosage | 25.0 (0.0) | 25.0 (0.0) | 25.0 (0.0) | 0.63 |
| Eplerenone | 20 (45.5%) | 10 (45.5%) | 10 (45.5%) | 0.89 |
| Daily dosage | 25.0 (25.0) | 37.5 (25.0) | 25.0 (25.0) | 0.58 |
| BB | 42 (95.5%) | 20 (90.1%) | 22 (100%) | 0.49 |
| ACE-i | 22 (50.0%) | 10 (45.5%) | 12 (54.5%) | 0.76 |
| ARB | 7 (15.9%) | 4 (18.2%) | 3 (13.6%) | 0.70 |
| ARNI | 3 (6.8%) | 2 (9.1%) | 1 (4.5%) | 0.61 |
| CCB | 4 (9.1%) | 2 (9.1%) | 2 (9.1%) | 0.99 |
| ASA | 2 (4.5%) | 1 (4.5%) | 1 (4.5%) | 0.99 |
| P2Y12i | 6 (13.6%) | 4 (18.2%) | 2 (9.1%) | 0.41 |
| VKA | 12 (27.3%) | 6 (27.3%) | 6 (27.3%) | 0.92 |
| NOAC | 26 (59.1%) | 11 (50.0%) | 15 (68.2%) | 0.29 |
| Fractioned heparin | 2 (4.5%) | 2 (9.1%) | 0 (0.0%) | 0.23 |
| Statin | 29 (65.9%) | 16 (72.7%) | 13 (59.1%) | 0.23 |
| SGLT-2 inhibitor | 16 (36.4%) | 4 (18.2%) | 12 (54.5%) | |
| ACE-i – angiotensin-converting enzyme inhibitor; ALT – alanine transaminase; ARB – angiotensin receptor blocker; ARNI – angiotensin receptor-neprilysin inhibitor; ASA – acetylsalicylic acid; AST – aspartate transaminase; AVR – aortic valve replacement; BB – beta-blocker; CABG – coronary artery bypass grafting; CAD – coronary artery disease; CCB – calcium channel blocker; CKD – chronic kidney disease; COPD – chronic obstructive pulmonary disease; eGFR – estimated glomerular filtration rate; INR – international normalized ratio; MI – myocardial infarction; NOAC – non-vitamin-K-antagonist oral anticoagulant; NT-proBNP – N-terminal pro-B-type natriuretic peptide; P2Y12i – P2Y12 inhibitor; PAD – peripheral artery disease; PCI – percutaneous coronary intervention; TIA – transient ischemic attack; SGLT-2 inhibitor – sodium-glucose cotransporter 2 inhibitor; VKA – vitamin K antagonist. | ||||